brickell biotech, inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. our management team and board of directors has extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. our strategy is to leverage this experience to in-license, acquire, develop and commercialize products that we believe can be successful in the global dermatology marketplace. our portfolio of five product candidates, all new molecular entities with relevant mechanism of actions in skin diseases, targets significant market opportunities.
Company profile
Ticker
FRTX
Exchange
Website
CEO
Robert Brown
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Brickell Biotech, Inc., VICAL INC, VICAL, INC.
SEC CIK
Corporate docs
IRS number
930948554
FRTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
18 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Termination of a Material Definitive Agreement
7 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
16 Feb 24
DEFA14A
Additional proxy soliciting materials
14 Feb 24
DEF 14A
Definitive proxy
17 Jan 24
DEFA14A
Additional proxy soliciting materials
16 Jan 24
PRE 14A
Preliminary proxy
5 Jan 24
8-K
Termination of a Material Definitive Agreement
3 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Dec 23
Transcripts
FRTX
Earnings call transcript
2022 Q3
13 Nov 22
FRTX
Earnings call transcript
2022 Q2
11 Aug 22
FRTX
Earnings call transcript
2022 Q2
11 Aug 22
FRTX
Earnings call transcript
2022 Q1
12 May 22
FRTX
Earnings call transcript
2022 Q1
12 May 22
FRTX
Earnings call transcript
2021 Q4
15 Mar 22
FRTX
Earnings call transcript
2021 Q4
15 Mar 22
FRTX
Earnings call transcript
2021 Q3
10 Nov 21
FRTX
Earnings call transcript
2021 Q3
9 Nov 21
FRTX
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
4
Change in insider ownership
23 Apr 24
4
Change in insider ownership
11 Apr 24
4
Change in insider ownership
5 Apr 24
4
Change in insider ownership
1 Apr 24
4
Change in insider ownership
21 Mar 24
4
Change in insider ownership
13 Mar 24
4
Change in insider ownership
28 Feb 24
4
Change in insider ownership
22 Feb 24
SC 13G/A
Exploration Capital, LLC
18 Jan 24
4
Change in insider ownership
17 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.02 mm | 12.02 mm | 12.02 mm | 12.02 mm | 12.02 mm | 12.02 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 775.08 k | (no burn) | 483.08 k |
Cash used (since last report) | n/a | n/a | n/a | 5.33 mm | n/a | 3.32 mm |
Cash remaining | n/a | n/a | n/a | 6.69 mm | n/a | 8.70 mm |
Runway (months of cash) | n/a | n/a | n/a | 8.6 | n/a | 18.0 |
Institutional ownership, Q3 2023
54.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 415.00 mm |
Total shares | 3.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 2.81 mm | $2.19 mm |
JBF Capital | 295.00 k | $286.15 mm |
GTS Securities | 50.10 k | $48.60 mm |
Geode Capital Management | 41.45 k | $40.21 mm |
Vanguard | 23.06 k | $22.37 mm |
Tower Research Capital | 10.22 k | $9.92 mm |
BLK Blackrock | 4.79 k | $4.65 mm |
Thrivent Trust Co of Tennessee | 916.00 | $1.00 k |
Steward Partners Investment Advisory | 709.00 | $688.00 k |
WFC Wells Fargo & Co. | 154.00 | $150.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.91 | 343 | 312.13 | 1,060,807 |
22 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.9 | 16,908 | 15.22 k | 1,060,464 |
19 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.91 | 4,277 | 3.89 k | 1,043,556 |
10 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.88 | 1,000 | 880.00 | 1,039,279 |
9 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.88 | 2,188 | 1.93 k | 1,038,279 |
5 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.91 | 1,050 | 955.50 | 1,036,091 |
4 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.91 | 3,400 | 3.09 k | 1,035,041 |
3 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.91 | 12,928 | 11.76 k | 1,031,641 |
1 Apr 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.89 | 354 | 315.06 | 1,018,713 |
28 Mar 24 | Exploration Capital | Common Stock | Buy | Acquire P | No | No | 0.9 | 2,586 | 2.33 k | 1,018,359 |